Growth Metrics

Merck (MRK) EBT (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -202.34%
Dec 31, 2025 -49.30%
Sep 30, 2025 34.93%
Jun 30, 2025 -15.31%
Mar 31, 2025 41.56%
Dec 31, 2024 1.96%
Sep 30, 2024 -31.90%
Jun 30, 2024 5.93%
Mar 31, 2024 377.13%
Dec 31, 2023 -136.41%
Sep 30, 2023 206.04%
Jun 30, 2023 -245.21%
Mar 31, 2023 3.90%
Dec 31, 2022 -1.95%
Sep 30, 2022 -20.15%
Jun 30, 2022 -7.69%
Mar 31, 2022 24.35%
Dec 31, 2021 -25.77%
Sep 30, 2021 206.70%
Jun 30, 2021 -42.52%
Mar 31, 2021 217.37%
Dec 31, 2020 -194.05%
Sep 30, 2020 -1.28%
Jun 30, 2020 -28.58%
Mar 31, 2020 355.53%
Dec 31, 2019 -164.00%
Sep 30, 2019 -27.98%
Jun 30, 2019 6.26%
Mar 31, 2019 17.78%
Dec 31, 2018 -2.29%
Sep 30, 2018 27.76%
Jun 30, 2018 55.09%
Mar 31, 2018 -28.42%
Dec 31, 2017 839.50%
Sep 30, 2017 -91.80%
Jun 30, 2017 21.77%
Mar 31, 2017 247.71%
Dec 31, 2016 -146.97%
Sep 30, 2016 91.95%
Jun 30, 2016 -7.39%
Mar 31, 2016 99.02%
Dec 31, 2015 -65.96%
Sep 30, 2015 197.03%
Jun 30, 2015 -41.56%
Mar 31, 2015 -88.31%
Dec 31, 2014 692.68%
Sep 30, 2014 -21.21%
Jun 30, 2014 -9.56%
Mar 31, 2014 70.69%
Dec 31, 2013 -19.67%
Sep 30, 2013 22.49%
Jun 30, 2013 -19.68%
Mar 31, 2013 16.19%
Dec 31, 2012 -39.86%
Sep 30, 2012 -17.24%
Jun 30, 2012 6.90%
Mar 31, 2012 58.57%
Dec 31, 2011 -32.78%
Sep 30, 2011 40.67%
Jun 30, 2011 -3.30%
Mar 31, 2011 193.21%
Dec 31, 2010 -472.49%
Sep 30, 2010 -59.87%
Jun 30, 2010 92.40%
Mar 31, 2010 -95.03%
Dec 31, 2009 2,019.44%
Sep 30, 2009 -20.83%
Jun 30, 2009 -31.59%